Lanreotide


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : IM Acromegaly; Carcinoid syndrome; Thyrotrophic adenoma Depot Initial: 30 mg every 14 days, up to 30 mg every 7-10 days depending on condition. SC Acromegaly; Carcinoid syndrome 60, 90 or 120 mg every 28 days. May reduce to 120 mg at intervals of up to 56 days for aromegaly patients who responded. Inadequately controlled cases: Max of 120 mg once every 28 days may be used.
Dosage Details
Intramuscular
Acromegaly, Carcinoid syndrome, Thyrotrophic adenoma
Adult: Initially, 30 mg by IM depot inj every 14 days. For acromegaly and carcinoid syndrome: May increase to 30 mg every 7-10 days; for thyrotrophic adenoma: May increase to 30 mg every 10 days.

Subcutaneous
Carcinoid syndrome, Acromegaly
Adult: 60, 90 or 120 mg by deep SC inj every 28 days. For acromegaly patients who responded: May reduce gradually to maintenance dose of 120 mg given at intervals of up to 56 days. For those who are not adequately controlled: Max dose of 120 mg once every 28 days may be used.
Renal Impairment
Subcutaneous:
Moderate to severe impairment: Initially, 60 mg by deep SC inj every 28 days for 3 mth; then adjust dose according to response.
Hepatic Impairment
Subcutaneous:
Moderate to severe impairment: Initially, 60 mg by deep SC inj every 28 days for 3 mth; then adjust dose according to response.
Special Precautions
Pregnancy, lactation. Check for gallstones before prolonged therapy and every 6-12 mth during treatment. Monitor for signs of tumour expansion. Monitor thyroid function.
Adverse Reactions
Transient local reaction at inj site, diarrhoea, steatorrhoea, abdominal discomfort, flatulence, anorexia, nausea, vomiting, gallstones (prolonged use), hypoglycaemia.
Parenteral/SC: C
Drug Interactions
May reduce intestinal absorption of coadministered drugs. May reduce serum concentration of ciclosporin. May increase bioavailability of bromocriptine. Dosage of insulin or oral hypoglycaemic drugs, β-blockers, calcium-channel blockers, or agents to control fluid and electrolyte balance may need to be adjusted.
Action
Description: Lanreotide is a somatostatin analogue which inhibits the release of growth hormone by binding to human somatostatin receptors (SSTR2 and 5). It also inhibits various endocrine, neuroendocrine, exocrine and paracrine functions.
Pharmacokinetics:
Absorption: Absolute bioavailability: 50-80%.
Excretion: IV: 2.5 hr (terminal half-life).
Storage
Store at 2-8°C (36-46°F). Do not freeze.
Disclaimer: This information is independently developed by MIMS based on Lanreotide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in